AzurRx BioPharma, Inc

(NASDAQ:AZRX)

Latest On AzurRx BioPharma, Inc (AZRX):

Date/Time Type Description Signal Details
2021-09-17 14:33 ESTNewsAzurRx BioPharma agrees to acquire First Wave Bio for $229 millionN/A
2021-09-17 14:31 ESTNewsAzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call TranscriptN/A
2021-09-17 14:29 ESTNewsAzurRx CEO highlights six GI clinical 'shots on goal' in First Wave Bio acquisitionN/A
2021-09-10 17:12 ESTNewsAzurRx activates new clinical trial sites in India for mid-stage FW-1022 COVID-19 trialN/A
2021-09-10 17:12 ESTNewsAzurRx BioPharma announces 1-for-10 reverse stock splitN/A
2021-09-09 21:01 ESTNewsAzurRx to initiate patient recruitment in Part 2 of mid-stage FW-1022 study in COVID-19N/A
2021-09-09 00:43 ESTNewsAzurRx Bio submits IND application for niclosamide in U.S.N/A
2021-08-19 02:18 ESTNewsAzurRx stock jumps 42% on positive MS1819 combo data for pancreatic insufficiency due to CFN/A
2021-08-12 13:04 ESTNewsAzurRx BioPharma shares rise 9% on FW-1022 COVID-19 trial enrollment updateN/A
2021-08-10 21:03 ESTNewsAzurRx BioPharma adds five sites to mid-stage FW-1022 COVID-19 trialN/A
2021-07-23 15:28 ESTNewsAzurRx Bio secures $5M capital raiseN/A
2021-07-22 19:32 ESTNewsAzurRx BioPharma slumps 16% after hours on $3M bought deal offeringN/A
2021-07-20 20:55 ESTNewsAzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 studyN/A
2021-05-02 21:33 ESTNewsAzurRx BioPharma: An AssessmentN/A
2021-04-14 04:16 ESTNewsAzurRx Biopharma engages PPD to manage niclosamide clinical trialN/A
2021-03-31 17:21 ESTNewsCLF, CHWY, OCGN and LCTX among premarket gainersN/A
2021-03-31 17:19 ESTNewsAzurRx slides after MS1819 fails in mid-stage cystic fibrosis studyN/A
2021-03-22 23:11 ESTNewsAzurRx completes enrollment in mid-stage MS1819 combo cystic fibrosis trialN/A
2021-03-16 20:05 ESTNewsAzurRx Bio soars on enrollment completion in study of MS1819 in cystic fibrosisN/A
2021-03-08 18:08 ESTNewsAzurRx BioPharma launches $10M registered direct offering priced at-the-marketN/A
2021-02-11 11:10 ESTAnalyst RatingThe Analyst Target Price has increased from $4 to $4.5.Buy
2021-02-10 07:27 ESTNewsTLRY, GLUU, ABEO and TYME among premarket gainersN/A
2021-02-10 07:27 ESTNewsAzurRx BioPharma jumps 18% over formulation trial for treatment of COVID-19-associated gastrointestinal infectionsN/A
2021-01-31 18:38 ESTNewsAzurRx Officially A COVID-19 Play - The Right Dose For Your PortfolioN/A
2021-01-28 20:51 ESTNewsAzurRx Bio completes enrollment in first cohort of mid-stage study of MS1819, shares up 13%N/A
2021-01-26 20:42 ESTNewsAzurRx adds two new trial sites in Europe for phase 2b OPTION 2 extension studyN/A
2021-01-21 21:24 ESTNewsAzurRx starts dosing in mid-stage cystic fibrosis study of MS1819N/A
2021-01-07 11:12 ESTAnalyst RatingThe Analyst Target Price has increased from $3.75 to $4.Buy
2021-01-04 21:39 ESTNewsAzurRx BioPharma, First Wave Bio in niclosamide licensing pact for gastrointestinal infectionsN/A
2021-01-02 15:12 ESTFinancialsCompany financials have been released.Neutral
2020-12-13 03:18 ESTFinancialsCompany financials have been released.Neutral
2020-12-01 11:47 ESTNewsAzurRx up 9% on advancement of mid-stage study of MS1819 in CF patientsN/A
2020-12-01 11:19 ESTAnalyst RatingThe Analyst Target Price has decreased from $3.8 to $3.75.Neutral
2020-11-19 03:18 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 19:13 ESTEarnings EstimateAn EPS average of -$0.13 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-15 11:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 17:13 ESTFinancialsCompany financials have been released.Neutral
2020-10-15 11:12 ESTNewsAzurRx Bio activates additional trial sites for lead candidateN/A
2020-09-24 00:12 ESTFinancialsCompany financials have been released.Neutral
2020-08-25 08:15 ESTAnalyst RatingThe Analyst Target Price has decreased from $4 to $3.8.Neutral
2020-08-18 02:40 ESTNewsAzurRx BioPharma launches European arm of cystic fibrosis studyN/A
2020-08-17 00:13 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 12:14 ESTNewsDosing underway in AzurRx Bio's OPTION 2 trial of MS1819 in cystic fibrosisN/A
2020-08-12 10:20 ESTNewsAzurRx rallies 41% on positive data on lead candidateN/A
2020-07-31 00:17 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 12:14 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:21 ESTFinancialsCompany financials have been released.Neutral
2020-07-21 11:50 ESTNewsAzurRx BioPharma closes $15.2M private placementN/A
2020-06-02 08:12 ESTEarnings EstimateAn EPS average of -$0.12 is estimated for the quarter ending on September 30, 2020.Buy
2020-06-02 08:12 ESTAnalyst RatingThe Analyst Target Price has decreased from $4.75 to $4.Neutral

About AzurRx BioPharma, Inc (AZRX):

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida with scientific operations in Langlade, France and clinical operations in Hayward, California.

AZRX Quotes by TradingView

See Advanced Chart

General

  • Name AzurRx BioPharma, Inc
  • Symbol AZRX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 10
  • Fiscal Year EndDecember
  • IPO Date2016-10-11
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.azurrx.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 7.7
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.14
  • Return on Assets -49%
  • Return on Equity -192%
  • Earnings Per Share -$0.90
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 105.09 million
  • EBITDA -15336710
  • Analyst Target Price $4.5
  • Book Value Per Share $0.49
View More

Share Statistics

  • Shares Outstanding 71.01 million
  • Shares Float 29.6 million
  • % Held by Insiders 1109%
  • % Held by Institutions 5.14%
  • Shares Short 645928
  • Shares Short Prior Month 2.27 million
  • Short Ratio 0.13
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.69
  • 52 Week High $2.5
  • 52 Week Low $0.51
  • 50 Day Moving Average 1.53
  • 200 Day Moving Average 1
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

AzurRx BioPharma, Inc (AZRX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

AzurRx BioPharma, Inc (AZRX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-16$N/A-$0.47-$0.13-254.72%
2020-06-302020-08-14$N/A-$0.17-$0.11-60.38%
2020-03-312020-05-15$N/A-$0.20-$0.11-76.52%
2019-12-312020-03-30$N/A-$0.02-$0.1687.75%
2019-09-302019-11-14$N/A-$0.17-$0.16-7.94%
2019-06-302019-08-13$N/A-$0.25-$0.22-13.64%
2019-03-312019-05-15$N/A-$0.26-$0.18-47.14%
2018-12-312019-03-31$N/A-$0.24-$0.18-33.33%
2018-09-302018-11-09$N/A-$0.15-$0.2023.74%
2018-06-302018-08-13$N/A-$0.22-$0.248.33%
2018-03-312018-05-14$N/A-$0.29-$0.18-61.11%
2017-12-312018-03-16$N/A-$0.21-$0.2410.64%
2017-09-302017-11-13$N/A-$0.28-$0.15-86.67%
2017-06-302017-08-14$N/A-$0.27-$0.270%
2017-03-312017-05-15$N/A-$0.29-$0.13-123.08%
2016-12-312017-03-31$N/A-$0.64-$0.13-392.31%
2016-09-302016-10-13$N/A-$0.33-$1.0568.84%

AzurRx BioPharma, Inc (AZRX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 1.55 million N/A 2.21 million
Income Before Tax N/A N/A -5.26 million N/A -4.19 million
Selling General Administrative N/A N/A 1.38 million N/A 1.87 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A -2.79 million N/A -4.08 million
Operating Income N/A N/A -2.93 million N/A -4.08 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A -110398
Net Income From Continuing Operations N/A N/A -5.26 million N/A -4.19 million
Net Income Applicable to Common Shares -13.47 million -4.7 million N/A -1.28 million -4.19 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -4340 N/A N/A
Change to Liabilities 661875 261227 N/A -1.02 million -339251
Total Cash Flow from Investing Activities N/A 1532 N/A -6855 -3906
Net Borrowings -137609 -167007 N/A 1.86 million -64714
Total Cash Flow from Financial Activities N/A N/A 2.76 million N/A 4.4 million
Change to Operating Activities -1.78 million 25805 N/A -919945 71468
Change in Cash N/A N/A 1.46 million N/A 239138
Total Cash from Operating Activities -2.7 million -1.34 million -1.29 million -3.23 million -4.15 million
Depreciation N/A N/A 140810 N/A 533341
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A -68829
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 1.28 million 331591 N/A 341623 -157997
Capital Expenditures N/A N/A 4340 N/A 3906
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 5.14 million N/A 6.23 million
Total Stockholder Equity N/A N/A 3.04 million N/A 3.2 million
Other Current Liabilities 900858 N/A N/A N/A 592676
Total Assets N/A N/A 8.18 million N/A 9.44 million
Common Stock 2888 2850 N/A 2680 2615
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -77.97 million -72.65 million -67.96 million -62.69 million -61.41 million
Other Liabilities 31469 43629 N/A N/A 414463
Other Assets 45841 36071 N/A 41047 48669
Cash N/A N/A 1.63 million N/A 1.55 million
Total Current Liabilities 2.63 million N/A 5.14 million N/A 5.82 million
Other Stockholder Equity -1.21 million -1.27 million N/A -1.27 million -1.36 million
Property, Plant & Equipment 158266 191607 N/A 159777 285354
Total Current Assets 11.54 million N/A 2.9 million N/A 3.73 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 9.09 million -5.83 million N/A -676526 -2.17 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.72 million N/A 1.32 million N/A 3.28 million

AzurRx BioPharma, Inc (AZRX) Chart:

AzurRx BioPharma, Inc (AZRX) News:

Below you will find a list of latest news for AzurRx BioPharma, Inc (AZRX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AzurRx BioPharma, Inc (AZRX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

AzurRx BioPharma, Inc (AZRX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001604/0001415889-20-001604-index.htm
2019-05-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1604191/000000000019008070/0000000000-19-008070-index.htm
2019-06-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1604191/000000000019009758/0000000000-19-009758-index.htm
2019-11-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1604191/000000000019015097/0000000000-19-015097-index.htm
2019-11-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1604191/000000000019015267/0000000000-19-015267-index.htm
2020-01-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1604191/000000000020000153/0000000000-20-000153-index.htm
2020-07-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1604191/000000000020006993/0000000000-20-006993-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1604191/000090266419001061/0000902664-19-001061-index.htm
2020-07-31DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000090571820000795/0000905718-20-000795-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1604191/000110580619000003/0001105806-19-000003-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1604191/000110580620000010/0001105806-20-000010-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000009/0001415889-19-000009-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000010/0001415889-19-000010-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000012/0001415889-19-000012-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000013/0001415889-19-000013-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000015/0001415889-19-000015-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000017/0001415889-19-000017-index.htm
2019-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000021/0001415889-19-000021-index.htm
2019-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000183/0001415889-19-000183-index.htm
2019-03-01DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000233/0001415889-19-000233-index.htm
2019-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000483/0001415889-19-000483-index.htm
2019-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000485/0001415889-19-000485-index.htm
2019-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000487/0001415889-19-000487-index.htm
2019-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000489/0001415889-19-000489-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000742/0001415889-19-000742-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000743/0001415889-19-000743-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000744/0001415889-19-000744-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000745/0001415889-19-000745-index.htm
2019-06-214/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000782/0001415889-19-000782-index.htm
2019-06-214/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000784/0001415889-19-000784-index.htm
2019-06-214/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000786/0001415889-19-000786-index.htm
2019-06-214/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000788/0001415889-19-000788-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000814/0001415889-19-000814-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000816/0001415889-19-000816-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000818/0001415889-19-000818-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919000820/0001415889-19-000820-index.htm
2019-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919001124/0001415889-19-001124-index.htm
2019-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919001126/0001415889-19-001126-index.htm
2019-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919001128/0001415889-19-001128-index.htm
2019-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919001130/0001415889-19-001130-index.htm
2019-10-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919001165/0001415889-19-001165-index.htm
2019-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588919001167/0001415889-19-001167-index.htm
2019-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000141588919001248/0001415889-19-001248-index.htm
2019-11-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1604191/000141588919001263/0001415889-19-001263-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000042/0001415889-20-000042-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000044/0001415889-20-000044-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000046/0001415889-20-000046-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000048/0001415889-20-000048-index.htm
2020-01-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000085/0001415889-20-000085-index.htm
2020-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000092/0001415889-20-000092-index.htm
2020-01-17DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000125/0001415889-20-000125-index.htm
2020-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000161/0001415889-20-000161-index.htm
2020-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000180/0001415889-20-000180-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000737/0001415889-20-000737-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000738/0001415889-20-000738-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000739/0001415889-20-000739-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000740/0001415889-20-000740-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000846/0001415889-20-000846-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000963/0001415889-20-000963-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000964/0001415889-20-000964-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000965/0001415889-20-000965-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000966/0001415889-20-000966-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000967/0001415889-20-000967-index.htm
2020-04-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000141588920000998/0001415889-20-000998-index.htm
2020-04-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001018/0001415889-20-001018-index.htm
2020-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001020/0001415889-20-001020-index.htm
2020-04-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001036/0001415889-20-001036-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001099/0001415889-20-001099-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001397/0001415889-20-001397-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001398/0001415889-20-001398-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001604/0001415889-20-001604-index.htm
2020-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001935/0001415889-20-001935-index.htm
2020-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001936/0001415889-20-001936-index.htm
2020-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001937/0001415889-20-001937-index.htm
2020-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001938/0001415889-20-001938-index.htm
2020-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1604191/000141588920001939/0001415889-20-001939-index.htm
2019-01-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1604191/000165495419000217/0001654954-19-000217-index.htm
2019-01-29SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1604191/000165495419000853/0001654954-19-000853-index.htm
2019-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419001776/0001654954-19-001776-index.htm
2019-02-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1604191/000165495419002000/0001654954-19-002000-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419003482/0001654954-19-003482-index.htm
2019-04-0110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1604191/000165495419003863/0001654954-19-003863-index.htm
2019-04-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1604191/000165495419003927/0001654954-19-003927-index.htm
2019-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419004024/0001654954-19-004024-index.htm
2019-04-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419004249/0001654954-19-004249-index.htm
2019-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419004728/0001654954-19-004728-index.htm
2019-04-26S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495419004818/0001654954-19-004818-index.htm
2019-04-3010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1604191/000165495419005061/0001654954-19-005061-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419005393/0001654954-19-005393-index.htm
2019-05-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1604191/000165495419005503/0001654954-19-005503-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419005904/0001654954-19-005904-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1604191/000165495419006140/0001654954-19-006140-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419006350/0001654954-19-006350-index.htm
2019-05-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419006517/0001654954-19-006517-index.htm
2019-06-05S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495419006935/0001654954-19-006935-index.htm
2019-06-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1604191/000165495419006936/0001654954-19-006936-index.htm
2019-06-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495419006937/0001654954-19-006937-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419007011/0001654954-19-007011-index.htm
2019-06-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419007090/0001654954-19-007090-index.htm
2019-06-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1604191/000165495419007552/0001654954-19-007552-index.htm
2019-06-21S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495419007553/0001654954-19-007553-index.htm
2019-06-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1604191/000165495419007556/0001654954-19-007556-index.htm
2019-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419008031/0001654954-19-008031-index.htm
2019-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419008108/0001654954-19-008108-index.htm
2019-07-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1604191/000165495419008322/0001654954-19-008322-index.htm
2019-07-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1604191/000165495419008366/0001654954-19-008366-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419008399/0001654954-19-008399-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1604191/000165495419009273/0001654954-19-009273-index.htm
2019-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419011103/0001654954-19-011103-index.htm
2019-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419011560/0001654954-19-011560-index.htm
2019-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419011683/0001654954-19-011683-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419011721/0001654954-19-011721-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419011722/0001654954-19-011722-index.htm
2019-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419011833/0001654954-19-011833-index.htm
2019-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419011913/0001654954-19-011913-index.htm
2019-10-28PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1604191/000165495419012042/0001654954-19-012042-index.htm
2019-11-06PRER14APreliminary Proxy Soliciting materialshttps://www.sec.gov/Archives/edgar/data/1604191/000165495419012382/0001654954-19-012382-index.htm
2019-11-07DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1604191/000165495419012478/0001654954-19-012478-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419012904/0001654954-19-012904-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1604191/000165495419012997/0001654954-19-012997-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419014137/0001654954-19-014137-index.htm
2019-12-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495419014302/0001654954-19-014302-index.htm
2019-12-31S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495419014339/0001654954-19-014339-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420000135/0001654954-20-000135-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420000304/0001654954-20-000304-index.htm
2020-01-13S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495420000383/0001654954-20-000383-index.htm
2020-01-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1604191/000165495420000385/0001654954-20-000385-index.htm
2020-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420000387/0001654954-20-000387-index.htm
2020-01-17424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1604191/000165495420000575/0001654954-20-000575-index.htm
2020-01-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1604191/000165495420000885/0001654954-20-000885-index.htm
2020-02-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495420001247/0001654954-20-001247-index.htm
2020-02-24S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495420001877/0001654954-20-001877-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420002162/0001654954-20-002162-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420002715/0001654954-20-002715-index.htm
2020-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420003382/0001654954-20-003382-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1604191/000165495420003530/0001654954-20-003530-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1604191/000165495420004656/0001654954-20-004656-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1604191/000165495420005632/0001654954-20-005632-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420007734/0001654954-20-007734-index.htm
2020-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420007820/0001654954-20-007820-index.htm
2020-07-24PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1604191/000165495420007995/0001654954-20-007995-index.htm
2020-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420008028/0001654954-20-008028-index.htm
2020-07-27S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495420008045/0001654954-20-008045-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420008470/0001654954-20-008470-index.htm
2020-08-07DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1604191/000165495420008642/0001654954-20-008642-index.htm
2020-08-11DEFR14ARevised definitive proxy soliciting materialshttps://www.sec.gov/Archives/edgar/data/1604191/000165495420008781/0001654954-20-008781-index.htm
2020-08-11SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1604191/000165495420008864/0001654954-20-008864-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420008881/0001654954-20-008881-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420008953/0001654954-20-008953-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1604191/000165495420009182/0001654954-20-009182-index.htm
2020-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420009422/0001654954-20-009422-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420010047/0001654954-20-010047-index.htm
2020-09-17RWRegistration Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/1604191/000165495420010208/0001654954-20-010208-index.htm
2020-09-17S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1604191/000165495420010210/0001654954-20-010210-index.htm
2020-09-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1604191/000165495420010211/0001654954-20-010211-index.htm
2020-09-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1604191/000165495420010271/0001654954-20-010271-index.htm
2019-06-07EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1604191/999999999519001307/9999999995-19-001307-index.htm
2019-06-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1604191/999999999519001439/9999999995-19-001439-index.htm
2020-01-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1604191/999999999520000092/9999999995-20-000092-index.htm
2020-09-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1604191/999999999520002515/9999999995-20-002515-index.htm

AzurRx BioPharma, Inc (AZRX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AzurRx BioPharma, Inc (AZRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1109%
Institutional Ownership: 514%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-12-31Alastair RiddellDirectorBuy7,500.001.047,800.00100,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000044/0001415889-20-000044-index.htm
2020-03-11Alastair RiddellDirectorBuy770.004.743,649.80100,770.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000740/0001415889-20-000740-index.htm
2020-03-11Alastair RiddellDirectorBuy264.004.741,251.36101,034.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000740/0001415889-20-000740-index.htm
2019-06-13CHARLES J CASAMENTODirectorBuy30,000.00101,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000744/0001415889-19-000744-index.htm
2020-03-11Alastair RiddellDirectorBuy2,507.003.9910,002.93103,541.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000740/0001415889-20-000740-index.htm
2020-03-11Alastair RiddellDirectorBuy2,755.003.6310,000.65106,296.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000740/0001415889-20-000740-index.htm
2019-06-13Alastair RiddellDirectorBuy30,000.00107,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000745/0001415889-19-000745-index.htm
2020-03-11CHARLES J CASAMENTODirectorBuy14,584.000.608,750.40108,584.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000739/0001415889-20-000739-index.htm
2020-03-11CHARLES J CASAMENTODirectorBuy8,414.001.048,750.56116,998.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000739/0001415889-20-000739-index.htm
2020-03-11Alastair RiddellDirectorBuy14,584.000.608,750.40123,635.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000740/0001415889-20-000740-index.htm
2020-03-11Alastair RiddellDirectorBuy8,414.001.048,750.56132,049.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000740/0001415889-20-000740-index.htm
2019-10-08JAMES SAPIRSTEINPRESIDENT AND CEOBuy200,000.00200,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919001167/0001415889-19-001167-index.htm
2018-05-02Edmund Burke Jr. Ross10% Share HolderBuy20,000.002.5050,000.002,421,010.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000021/0001415889-19-000021-index.htm
2018-12-27Edmund Burke Jr. Ross10% Share HolderBuy42,922.001.1850,647.962,463,932.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000021/0001415889-19-000021-index.htm
2018-12-27Edmund Burke Jr. Ross10% Share HolderBuy23,200.001.1326,216.002,487,132.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000021/0001415889-19-000021-index.htm
2018-12-28Edmund Burke Jr. Ross10% Share HolderBuy29,575.001.1834,898.502,516,707.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000021/0001415889-19-000021-index.htm
2018-12-31Edmund Burke Jr. Ross10% Share HolderBuy23,848.001.1226,709.762,540,555.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000021/0001415889-19-000021-index.htm
2018-12-28Johan M. SpoorPRESIDENT AND CEOBuy38,583.001.3049,968.84338,617.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000017/0001415889-19-000017-index.htm
2018-12-28EDWARD BORKOWSKIDirectorBuy7,500.001.299,675.00349,126.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000013/0001415889-19-000013-index.htm
2019-03-31EDWARD BORKOWSKIDirectorBuy7,500.002.4218,150.00356,626.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000489/0001415889-19-000489-index.htm
2019-06-30EDWARD BORKOWSKIDirectorBuy7,500.001.7012,750.00364,126.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000820/0001415889-19-000820-index.htm
2019-09-30EDWARD BORKOWSKIDirectorBuy7,500.000.604,500.00371,626.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919001124/0001415889-19-001124-index.htm
2018-12-28Vern Lee SchrammDirectorBuy7,500.001.299,675.0037,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000012/0001415889-19-000012-index.htm
2019-12-31EDWARD BORKOWSKIDirectorBuy7,500.001.047,800.00379,126.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000048/0001415889-20-000048-index.htm
2019-06-13EDWARD BORKOWSKIDirectorBuy30,000.00386,626.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000743/0001415889-19-000743-index.htm
2020-03-10EDWARD BORKOWSKIDirectorBuy14,584.000.608,750.40393,710.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000737/0001415889-20-000737-index.htm
2020-03-10EDWARD BORKOWSKIDirectorBuy8,414.001.048,750.56402,124.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000737/0001415889-20-000737-index.htm
2020-03-10EDWARD BORKOWSKIDirectorBuy1,319.004.746,252.06403,443.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000737/0001415889-20-000737-index.htm
2020-03-10EDWARD BORKOWSKIDirectorBuy6,330.004.7430,004.20409,773.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000737/0001415889-20-000737-index.htm
2019-03-31Vern Lee SchrammDirectorBuy7,500.002.4218,150.0045,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000483/0001415889-19-000483-index.htm
2019-06-30Vern Lee SchrammDirectorBuy7,500.001.7012,750.0052,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000814/0001415889-19-000814-index.htm
2018-12-28CHARLES J CASAMENTODirectorBuy9,000.001.4112,690.0056,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000010/0001415889-19-000010-index.htm
2019-09-30Vern Lee SchrammDirectorBuy7,500.000.604,500.0060,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919001126/0001415889-19-001126-index.htm
2018-12-28Maged ShenoudaCHIEF FINANCIAL OFFICERBuy20,000.001.3126,214.0062,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000015/0001415889-19-000015-index.htm
2018-12-28CHARLES J CASAMENTODirectorBuy7,500.001.299,675.0064,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000010/0001415889-19-000010-index.htm
2019-12-31Vern Lee SchrammDirectorBuy7,500.001.047,800.0067,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000042/0001415889-20-000042-index.htm
2018-12-28Alastair RiddellDirectorBuy7,500.001.299,675.0070,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000009/0001415889-19-000009-index.htm
2019-03-31CHARLES J CASAMENTODirectorBuy7,500.002.4218,150.0071,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000487/0001415889-19-000487-index.htm
2019-06-13Vern Lee SchrammDirectorBuy30,000.0075,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000742/0001415889-19-000742-index.htm
2019-03-31Alastair RiddellDirectorBuy7,500.002.4218,150.0077,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000485/0001415889-19-000485-index.htm
2019-06-30CHARLES J CASAMENTODirectorBuy7,500.001.7012,750.0079,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000816/0001415889-19-000816-index.htm
2020-03-11Vern Lee SchrammDirectorBuy14,584.000.608,750.4082,084.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000738/0001415889-20-000738-index.htm
2019-06-30Alastair RiddellDirectorBuy7,500.001.7012,750.0085,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919000818/0001415889-19-000818-index.htm
2019-09-30CHARLES J CASAMENTODirectorBuy7,500.000.604,500.0086,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919001128/0001415889-19-001128-index.htm
2020-03-11Vern Lee SchrammDirectorBuy8,414.001.048,750.5690,498.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000738/0001415889-20-000738-index.htm
2019-09-30Alastair RiddellDirectorBuy7,500.000.604,500.0092,500.00https://www.sec.gov/Archives/edgar/data/1604191/000141588919001130/0001415889-19-001130-index.htm
2019-12-31CHARLES J CASAMENTODirectorBuy7,500.001.047,800.0094,000.00https://www.sec.gov/Archives/edgar/data/1604191/000141588920000046/0001415889-20-000046-index.htm